

**Consultation on draft guideline – deadline for comments** 5pm on 6 November 2017 **email:** [Lymedisease@nice.org.uk](mailto:Lymedisease@nice.org.uk)

Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.

We would like to hear your views on the draft recommendations presented in the short version and any comments you may have on the evidence presented in the full version. We would also welcome views on the Equality Impact Assessment.

**We would like to hear your views on these questions:**

1. Which areas will have the biggest impact on practice and be challenging to implement? Please say for whom and why.
2. Would implementation of any of the draft recommendations have significant cost implications?
3. What would help users overcome any challenges? (For example, existing practical resources or national initiatives, or examples of good practice.)
4. Do you agree with the committee's proposed recommendations to standardise dosage and duration of treatment across different presentations?
5. Based on explanations in the evidence reviews for the management of Lyme disease, is it appropriate for specialists to consider the use of doxycycline in children under 12? If so, should this be limited to children aged 9 and above or available for consideration in any child aged 2 or above?

See section 3.9 of [Developing NICE guidance: how to get involved](#) for suggestions of general points to think about when commenting.

## Lyme disease

Consultation on draft guideline – deadline for comments 5pm on 6 November 2017 **email:** [Lymedisease@nice.org.uk](mailto:Lymedisease@nice.org.uk)

<b>Organisation name – Stakeholder or respondent</b> (if you are responding as an individual rather than a registered stakeholder please leave blank):		Royal Pharmaceutical Society		
<b>Disclosure</b> Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry.		N/A		
<b>Name of commentator person completing form:</b>		Sabes Thurairasa		
<b>Type</b>		[office use only]		
<b>Comment number</b>	<b>Document</b> (full version, short version or the appendices)	<b>Page number</b> Or 'general' for comments on the whole document	<b>Line number</b> Or 'general' for comments on the whole document	<b>Comments</b>  Insert each comment in a new row. Do not paste other tables into this table, because your comments could get lost – type directly into this table.
Example 1	Short	16	45	We are concerned that this recommendation may imply that .....
Example 2	1	16	45	Question 1: This recommendation will be a challenging change in practice because .....

Please return to: [Lymedisease@nice.org.uk](mailto:Lymedisease@nice.org.uk)

## Lyme disease

**Consultation on draft guideline – deadline for comments** 5pm on 6 November 2017 **email:** [Lymedisease@nice.org.uk](mailto:Lymedisease@nice.org.uk)

Example 3	4	16	45	Question 3: Our trust has had experience of implementing this approach and would be willing to submit its experiences to the NICE shared learning database. Contact.....
General				The Royal Pharmaceutical Society welcomes the NICE guideline on Lyme disease. People commonly present to community pharmacies following bites and symptoms of rash or other symptoms of Lyme Disease. Pharmacists would be able to advise patients and refer to a prescriber where appropriate. Pharmacists play an important role in ensuring that appropriate antibiotic prescribing occurs and support patients with adherence to antibiotic therapies.
2				
3				
4				
5				
6				

Insert extra rows as needed

### Checklist for submitting comments

- Use this comment form and submit it as a Word document (not a PDF).
- **Where commenting on one of the 15 guideline chapters, please enter the number only in the document column (essential so we know which document you are commenting on), and the page and line numbers.**
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include page and line number (not section number) of the text each comment is about.
- Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
- Do not paste other tables into this table – type directly into the table.
- Underline and highlight any confidential information or other material that you do not wish to be made public.
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, comment forms do not include attachments such as research articles, letters or leaflets (for copyright reasons).  
We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.

You can see any guidance that we have produced on topics related to this guideline by checking [NICE Pathways](#).

**Note:** We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Please return to: [Lymedisease@nice.org.uk](mailto:Lymedisease@nice.org.uk)

## Lyme disease

**Consultation on draft guideline – deadline for comments** 5pm on 6 November 2017 **email:** [Lymedisease@nice.org.uk](mailto:Lymedisease@nice.org.uk)

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.